{"id":420150,"date":"2021-01-25T08:03:44","date_gmt":"2021-01-25T13:03:44","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=420150"},"modified":"2021-01-25T08:03:44","modified_gmt":"2021-01-25T13:03:44","slug":"seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/","title":{"rendered":"Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">GERMANTOWN, Md.<\/span>, <span class=\"xn-chron\">Jan. 25, 2021<\/span> \/PRNewswire\/ &#8212; Seneca Biopharma, Inc,\u00a0(NASDAQ:SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,\u00a0today announced that it received notice from\u00a0The NASDAQ Stock Market LLC\u00a0(NASDAQ) on\u00a0January 22, 2021\u00a0indicating that the company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. <\/p>\n<p>On <span class=\"xn-chron\">March 30, 2020<\/span>, <span class=\"xn-location\">Seneca<\/span> received a written notice from the NASDAQ Stock Market LLC that it was not in compliance with NASDAQ Listing Rule 5550(a)(2) as a result of the minimum bid price of its common stock being below <span class=\"xn-money\">$1.00<\/span> per share for 30 consecutive business days. At the time, <span class=\"xn-location\">Seneca<\/span> had until <span class=\"xn-chron\">September 28, 2020<\/span>, to regain compliance. On <span class=\"xn-chron\">April 17, 2020<\/span>, <span class=\"xn-location\">Seneca<\/span> received a subsequent written notice that as a result of a rule change, the NASDAQ tolled the compliance period through <span class=\"xn-chron\">June 30, 2020<\/span>. As a result, <span class=\"xn-location\">Seneca<\/span> had until <span class=\"xn-chron\">December 10, 2020<\/span> to regain compliance. On <span class=\"xn-chron\">December 11, 2020<\/span>, as a result of <span class=\"xn-location\">Seneca<\/span> request for additional time, <span class=\"xn-location\">Seneca<\/span> received written notification from NASDAQ that <span class=\"xn-location\">Seneca<\/span> was granted a 180-day extension to regain compliance with NASDAQ&#8217;s minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2). Accordingly, <span class=\"xn-location\">Seneca<\/span> had until <span class=\"xn-chron\">June 9, 2021<\/span> to meet the bid price requirement.<\/p>\n<p>\n        <b>About Seneca Biopharma, Inc. <br \/><\/b>Seneca Biopharma, Inc., is a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need. On <span class=\"xn-chron\">December 17, 2020<\/span>, <span class=\"xn-location\">Seneca<\/span> announced that it had entered into a definitive Merger Agreement with Leading BioSciences, Inc. (LBS), a privately held company focused on developing novel therapeutics to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. Upon completion of the merger, the company is expected to operate under the name Palisade Bio, Inc. and trade on the NASDAQ Capital Market under the ticker symbol PALI.<\/p>\n<p>\n        <b>Cautionary Statement\u00a0 <br \/><\/b>This news release contains &#8220;forward-looking statements&#8221; made pursuant to the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek&#8221; or &#8220;will.&#8221; Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in <span class=\"xn-location\">Seneca&#8217;s<\/span> periodic reports filed with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended <span class=\"xn-chron\">December 31, 2019<\/span>, its Quarterly Reports on Form 10-Q as well as and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.<\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY57356&amp;sd=2021-01-25\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements-301213789.html\">http:\/\/www.prnewswire.com\/news-releases\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements-301213789.html<\/a><\/p>\n<p>SOURCE  Seneca Biopharma, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY57356&amp;Transmission_Id=202101250800PR_NEWS_USPR_____NY57356&amp;DateId=20210125\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire GERMANTOWN, Md., Jan. 25, 2021 \/PRNewswire\/ &#8212; Seneca Biopharma, Inc,\u00a0(NASDAQ:SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,\u00a0today announced that it received notice from\u00a0The NASDAQ Stock Market LLC\u00a0(NASDAQ) on\u00a0January 22, 2021\u00a0indicating that the company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. On March 30, 2020, Seneca received a written notice from the NASDAQ Stock Market LLC that it was not in compliance with NASDAQ Listing Rule 5550(a)(2) as a result of the minimum bid price of its common stock being below $1.00 per share for 30 consecutive business days. At the time, Seneca had until September &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-420150","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire GERMANTOWN, Md., Jan. 25, 2021 \/PRNewswire\/ &#8212; Seneca Biopharma, Inc,\u00a0(NASDAQ:SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,\u00a0today announced that it received notice from\u00a0The NASDAQ Stock Market LLC\u00a0(NASDAQ) on\u00a0January 22, 2021\u00a0indicating that the company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. On March 30, 2020, Seneca received a written notice from the NASDAQ Stock Market LLC that it was not in compliance with NASDAQ Listing Rule 5550(a)(2) as a result of the minimum bid price of its common stock being below $1.00 per share for 30 consecutive business days. At the time, Seneca had until September &hellip; Continue reading &quot;Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-25T13:03:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY57356&amp;sd=2021-01-25\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements\",\"datePublished\":\"2021-01-25T13:03:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\\\/\"},\"wordCount\":522,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY57356&amp;sd=2021-01-25\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\\\/\",\"name\":\"Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY57356&amp;sd=2021-01-25\",\"datePublished\":\"2021-01-25T13:03:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY57356&amp;sd=2021-01-25\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY57356&amp;sd=2021-01-25\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/","og_locale":"en_US","og_type":"article","og_title":"Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements - Market Newsdesk","og_description":"PR Newswire GERMANTOWN, Md., Jan. 25, 2021 \/PRNewswire\/ &#8212; Seneca Biopharma, Inc,\u00a0(NASDAQ:SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,\u00a0today announced that it received notice from\u00a0The NASDAQ Stock Market LLC\u00a0(NASDAQ) on\u00a0January 22, 2021\u00a0indicating that the company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. On March 30, 2020, Seneca received a written notice from the NASDAQ Stock Market LLC that it was not in compliance with NASDAQ Listing Rule 5550(a)(2) as a result of the minimum bid price of its common stock being below $1.00 per share for 30 consecutive business days. At the time, Seneca had until September &hellip; Continue reading \"Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-25T13:03:44+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY57356&amp;sd=2021-01-25","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements","datePublished":"2021-01-25T13:03:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/"},"wordCount":522,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY57356&amp;sd=2021-01-25","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/","name":"Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY57356&amp;sd=2021-01-25","datePublished":"2021-01-25T13:03:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY57356&amp;sd=2021-01-25","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY57356&amp;sd=2021-01-25"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seneca-biopharma-regains-compliance-with-nasdaq-listing-requirements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/420150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=420150"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/420150\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=420150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=420150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=420150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}